Exploring the innovation behind acquired companies
Acquisitions
Jul 16, 2026
•
10 min read
SSRI/SNRI powerhouse bets on neuroplasticity for depression
Jul 7, 2026
13 min read
How R. Scott Struthers and his crew from Neurocrine went out on their own and struck gold in rare metabolic disease
Jul 6, 2026
8 min read
Another preclinical ADC payload company exits north of a billion dollars
Jul 2, 2026
Regenerative medicine titans join forces to grow a thymus
Jul 1, 2026
12 min read
Neutralizing the viral ghosts that haunt kidney transplant patients
Jun 29, 2026
Unleashing apoptotic p53 on myelofibrosis
7 min read
M&A alchemy with a COPD sweetener
Jun 22, 2026
Paragon's long-acting atopic dermatitis & asthma pipeline pays off
Jun 18, 2026
Qing Dong and Gene Hung pull off a third act with oral immunology me-betters
Jun 16, 2026
11 min read
Ted Price's hunt for non-opioid painkillers pays off
Jun 9, 2026
17 min read
Bolting on a three-headed hydra of targeted lung cancer drugs
Jun 8, 2026
A bold bet on novel discoveries in a rare bleeding disorder pays off
An ADC degrader play with a Nobel and rock & roll twist
Jun 1, 2026
A contrarian bet on skeletal myosin pays off
May 26, 2026
9 min read
Re-entering the vaccine market with multiple sclerosis (MS) upside
May 20, 2026
A founder-led startup aiming to solve gene therapy's "last mile" problem
May 6, 2026
A long-acting diabetic eye disease play
May 4, 2026
Scooping a reverse merger for a TCE pipeline
Apr 29, 2026
An oral HAE play
Apr 27, 2026
19 min read
A differentiated JAK play
Apr 21, 2026
Digging into the in vivo CAR-T gold rush
Apr 15, 2026
A bet on dual-payload ADCs
Apr 7, 2026
The advent of 3rd generation ADCs
Apr 6, 2026
The story of the first FDA approved drug for Prader-Willi Syndrome (PWS) in patients four years of age and older
Apr 5, 2026
Rise of selective OX2 agonists for narcolepsy
